News

Published on 22 Jun 2023 on Benzinga via Yahoo Finance

Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial

Article preview image

Vaxxinity Inc (NASDAQ: VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease (PD).

UB-312 is a synthetic peptide vaccine targeting aggregated forms of aSyn, which plays a central role in PD development and progression.

Read the rest of the article
NASDAQ.VAXX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.11%

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.11%

Investing.com 24 Apr 2024
Why Vaxxinity (VAXX) Shares Are Volatile Today - Vaxxinity (NASDAQ:VAXX)

Vaxxinity Inc VAXX shares are trading lower by 10% to $0.24 during Tuesday’s session. The stock i...

Benzinga 23 Apr 2024
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% By Investing.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67%

Investing.com 22 Apr 2024
Why Vaxxinity (VAXX) Shares Are Down Nearly 50% - Vaxxinity (NASDAQ:VAXX)

Vaxxinity Inc VAXX shares are trading lower by 47% to $0.25 during Monday’s session after the com...

Benzinga 22 Apr 2024
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's...

Shares of Vaxxinity, Inc. VAXX fell sharply during Monday's session after the company announced i...

Benzinga 22 Apr 2024
Gold Falls Sharply; Matterport Shares Spike Higher - Albertsons Companies (NYSE:ACI), Hepion...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on...

Benzinga 22 Apr 2024
Dow Jumps Over 100 Points; Chicago Fed National Activity Rises In March - Moolec Science...

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday. Fol...

Benzinga 22 Apr 2024
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

For Immediate Release Chicago, IL – December 12, 2023 – Zacks.com announces the list of stocks fe...

Zacks via Yahoo Finance 12 Dec 2023
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m...

Key Insights The considerable ownership by private companies in Vaxxinity indicates that they col...

Simply Wall St. via Yahoo Finance 10 Oct 2023
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)

Vaxxinity, Inc. (VAXX) has been beaten down lately with too much selling pressure. While the stoc...

Zacks via Yahoo Finance 7 Sep 2023

Copyright Statfolio @ 2024

Social Accounts